Robert F. Kennedy Jr. had fired all 17 members of a key vaccine panel. Now his new panel recommended a new infant RSV vaccine ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

In a move that has left many public health observers reeling, a newly appointed vaccine committee under Health and Human Services Secretary Robert F. Kennedy Jr. has voted to recommend an RSV shot for ...

Find patient medical information for Abrysvo (respiratory syncytial virus vaccine) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings ...

By the second half of 2024, Abrysvo had a 48% share in pharmacies and other locations, Pfizer said. Abrysvo sales have pulled ...

This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the ...

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

This release contains forward-looking information about ABRYSVO, including its potential benefits and a vote by ACIP to expand its recommendation to include adults 50-59 years of age at increased ...

ABRYSVO ® is a vaccine indicated in the U.S. for: the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in people 60 years of age and older ...

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 ; NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that the ...